Overview
PGxAI provides an AI-powered pharmacogenomics platform that delivers personalized drug selection, dosage recommendations, and interaction predictions using machine learning and real-world data. It supports biopharmaceutical sponsors, CROs, and healthcare providers by optimizing clinical trial design, reducing adverse drug reactions, and generating pharmacogenomic reports covering over 730 drugs and 40 genes. The platform integrates generative models, LLMs, and partnerships like Sequencing.com and Novo Genomics to enhance precision medicine.
Frequently asked questions
- What capabilities does PGxAI offer for clinical trials?
- PGxAI empowers CROs and biopharmaceutical sponsors with PGx insights to identify optimal patient cohorts, predict drug-gene interactions, and optimize protocols, reducing trial failures and streamlining design.
- What is the coverage of PGxAI's pharmacogenomic reports?
- Reports cover over 730 drugs and 40 genes, providing personalized drug implications, up to five times the coverage of competitors, to reduce adverse reactions.
- In which geographies does PGxAI operate or partner?
- PGxAI, based in Palo Alto, partners with Sequencing.com for global reach and Novo Genomics to scale services across the Kingdom of Saudi Arabia (KSA).